• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.

作者信息

Avigan Zachary M, Bodnar Saoirse, Pan Darren, Catlett Jerrel, Richter Joshua, Sanchez Larysa J, Rodriguez Cesar, Rossi Adriana C, Richard Shambavi, Jagannath Sundar, Cho Hearn Jay, Parekh Samir, Thibaud Santiago

机构信息

Division of Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

出版信息

Blood Adv. 2025 Jan 14;9(1):202-206. doi: 10.1182/bloodadvances.2024014255.

DOI:10.1182/bloodadvances.2024014255
PMID:39383457
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11758837/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d932/11758837/1b393d317e42/BLOODA_ADV-2024-014255-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d932/11758837/dfb7c0b369b7/BLOODA_ADV-2024-014255-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d932/11758837/1b393d317e42/BLOODA_ADV-2024-014255-gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d932/11758837/dfb7c0b369b7/BLOODA_ADV-2024-014255-gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d932/11758837/1b393d317e42/BLOODA_ADV-2024-014255-gr2.jpg

相似文献

1
Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival.在达菲阴性骨髓瘤患者中，BCMA嵌合抗原受体T细胞（CAR-T）治疗后中性粒细胞延迟恢复不影响严重感染或生存。
Blood Adv. 2025 Jan 14;9(1):202-206. doi: 10.1182/bloodadvances.2024014255.
2
Safety and Efficacy of BCMA CAR-T Cell Therapy in Older Patients With Multiple Myeloma.BCMA CAR-T 细胞疗法在多发性骨髓瘤老年患者中的安全性和疗效。
Transplant Cell Ther. 2023 Jun;29(6):350-355. doi: 10.1016/j.jtct.2023.03.012. Epub 2023 Mar 17.
3
BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma.靶向B细胞成熟抗原（BCMA）的嵌合抗原受体T细胞（CAR-T）疗法作为浆母细胞性骨髓瘤患者的挽救疗法
Hematology. 2025 Dec;30(1):2481555. doi: 10.1080/16078454.2025.2481555. Epub 2025 Mar 27.
4
BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.BCMA CAR-T 疗法联合泊马度胺是治疗复发/难治性多发性骨髓瘤的一种安全有效的方法。
J Transl Med. 2024 Nov 29;22(1):1087. doi: 10.1186/s12967-024-05772-w.
5
Preclinical delayed toxicity studies of BCMA CAR T-cell injection in B-NDG mice with multiple myeloma.BCMA CAR T 细胞注射在多发性骨髓瘤 B-NDG 小鼠中的临床前迟发性毒性研究。
Front Immunol. 2024 Nov 13;15:1435934. doi: 10.3389/fimmu.2024.1435934. eCollection 2024.
6
High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma.CD38 和 BCMA 双特异性 CAR-T 在复发或难治性多发性骨髓瘤中的高效和安全性。
J Exp Clin Cancer Res. 2022 Jan 3;41(1):2. doi: 10.1186/s13046-021-02214-z.
7
Recovery-model: A model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma.恢复模型：复发/难治性多发性骨髓瘤中 CAR T 细胞相关血小板减少症的模型。
Thromb Res. 2023 Jul;227:62-70. doi: 10.1016/j.thromres.2023.05.016. Epub 2023 May 22.
8
Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma.桥接强度与多发性骨髓瘤患者接受BCMA嵌合抗原受体T细胞（CAR-T）治疗后造血恢复受损有关。
Blood Adv. 2025 Aug 26;9(16):4151-4166. doi: 10.1182/bloodadvances.2024015732.
9
Mechanisms and salvage treatments in patients with multiple myeloma relapsed post-BCMA CAR-T cell therapy.BCMA 嵌合抗原受体 T 细胞治疗后复发的多发性骨髓瘤患者的机制和挽救治疗。
Front Immunol. 2024 Oct 22;15:1433774. doi: 10.3389/fimmu.2024.1433774. eCollection 2024.
10
[Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells].利用嵌合抗原受体工程化T细胞靶向多发性骨髓瘤中的BCMA
Zhonghua Xue Ye Xue Za Zhi. 2019 Oct 14;40(10):804-811. doi: 10.3760/cma.j.issn.0253-2727.2019.10.002.

本文引用的文献

1
Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study).嵌合抗原受体 T 细胞（CAR-T）疗法治疗大 B 细胞淋巴瘤后的输血需求：预测因素和结果（DESCAR-T 研究）。
Blood Adv. 2024 Mar 26;8(6):1573-1585. doi: 10.1182/bloodadvances.2023011727.
2
Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality.应用 CAR-T 后 EHA/EBMT 分级评估 ICAHT：感染和死亡率的比较发生率和相关性。
Blood Adv. 2024 Apr 23;8(8):1857-1868. doi: 10.1182/bloodadvances.2023011767.
3
Inhibition of PLK4 remodels histone methylation and activates the immune response via the cGAS-STING pathway in TP53-mutated AML.
PLK4 抑制通过 cGAS-STING 通路重塑组蛋白甲基化并激活 TP53 突变型 AML 中的免疫反应。
Blood. 2023 Dec 7;142(23):2002-2015. doi: 10.1182/blood.2023019782.
4
Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion.CD19 CAR-T 治疗后严重的血液毒性与抑制性免疫失调和有限的 CAR-T 扩增有关。
Sci Adv. 2023 Sep 22;9(38):eadg3919. doi: 10.1126/sciadv.adg3919.
5
The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma.CAR-HEMATOTOX 评分作为接受 BCMA 靶向 CAR-T 治疗复发/难治性多发性骨髓瘤患者毒性和反应的预后模型。
J Hematol Oncol. 2023 Jul 31;16(1):88. doi: 10.1186/s13045-023-01465-x.
6
Development of Duffy Null-Specific Absolute Neutrophil Count Reference Ranges.达菲阴性特异性绝对中性粒细胞计数参考范围的制定。
JAMA. 2023 Jun 20;329(23):2088-2089. doi: 10.1001/jama.2023.7467.
7
Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations.免疫效应细胞相关血液学毒性：EHA/EBMT 共识分级和最佳实践建议。
Blood. 2023 Sep 7;142(10):865-877. doi: 10.1182/blood.2023020578.
8
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.西达基奥仑赛或标准护理用于来那度胺难治性多发性骨髓瘤。
N Engl J Med. 2023 Jul 27;389(4):335-347. doi: 10.1056/NEJMoa2303379. Epub 2023 Jun 5.
9
Eligibility criteria and enrollment of a diverse racial and ethnic population in multiple myeloma clinical trials.多发性骨髓瘤临床试验中不同种族和民族人群的入选标准和纳入情况。
Blood. 2023 Jul 20;142(3):235-243. doi: 10.1182/blood.2022018657.
10
Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT Transplant Complications Working Party.CD19 CAR T 细胞治疗后严重细胞减少症：来自 EBMT 移植并发症工作组的回顾性研究。
J Immunother Cancer. 2023 Apr;11(4). doi: 10.1136/jitc-2022-006406.